AGM
KPTI icon

Alpine Global Management’s Karyopharm Therapeutics KPTI Stock Holding History

Alpine Global Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,139
Closed -$58K – 295
2022
Q4 		$58K Buy
+1,139
New +$79K 0.02% 385

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Alpine Global Management's KPTI Position: Q1 2023 in Review

Alpine Global Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2023, closing a stake of 1,139 shares — an estimated $58K sold.

Alpine Global Management first reported a position in KPTI in Q4 2022 and held it in 1 quarter. The position peaked at $58K in Q4 2022. 129 funds tracked by Wall St. Rank hold KPTI as of Q1 2023.

  • Alpine Global Management reported no remaining Karyopharm Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Alpine Global Management sold 1,139 Karyopharm Therapeutics shares in Q1 2023, an estimated $58K.
  • Alpine Global Management first reported a position in Karyopharm Therapeutics in Q4 2022 and held it in 1 quarter.
  • Alpine Global Management's Karyopharm Therapeutics position peaked at $58K in Q4 2022.
  • 129 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2023.

Based on Alpine Global Management's 13F filing for Q1 2023, filed 15 May 2023.